Penetration of ASM 981 in canine skin: a comparative study.
ASM 981 has been developed for topical treatment of inflammatory skin diseases. It specifically inhibits the production and release of pro-inflammatory cytokines. We measured the skin penetration of ASM 981 in canine skin and compared penetration in living and frozen skin. To make penetration of ASM 981 visible in dog skin, tritium labelled ASM 981 was applied to a living dog and to defrosted skin of the same dog. Using qualitative autoradiography the radioactive molecules were detected in the lumen of the hair follicles until the infundibulum, around the superficial parts of the hair follicles and into a depth of the dermis of 200 to 500 microm. Activity could not be found in deeper parts of the hair follicles, the dermis or in the sebaceous glands. Penetration of ASM 981 is low in canine skin and is only equally spread in the upper third of the dermis 24 hours after application. Penetration in frozen skin takes even longer than in living canine skin but shows the same distribution.
Gutzwiller
Meret E Ricklin
ME
Novartis Centre de Recherche Santé Animale SA, St-Aubin, Switzerland.
Reist
Martin
M
Persohn
Elke
E
Peel
John E
JE
Roosje
Petra J
PJ
D000279:Administration, Cutaneous; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000378:metabolism*; D015925:Cryopreservation; D004285:Dogs; D004353:Drug Evaluation, Preclinical / Q000379:methods; D012867:Skin / Q000033:anatomy & histology / Q000378:metabolism*; D012869:Skin Absorption; D016559:Tacrolimus / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; C117268:pimecrolimus; D016559:Tacrolimus